Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is a heterogeneous clinical, genetic, and neuropathological disorder. Clinical diagnosis and prediction of neuropathological substrates are hampered by heterogeneous pictures. Diagnostic markers are key in clinical trials to differentiate FTD from other neurodegenerative dementias. In the same view, identifying the neuropathological hallmarks of the disease is key in light of future disease-modifying treatments. The aim of the present review is to unravel the progress in biomarker discovery, discussing the potential applications of available biological, imaging, and neurophysiological markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationClinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608 · cited 1×
“Moreover, the visual evaluation of FDG-PET images provided greater diagnostic accuracy in differentiating FTD from other dementias [84]; more recently, this single-subject approach has been standardized using an optimized statistical parametric mapping (SPM) [85].”
Method[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 1×
“, [18F]AV-1451 [88] and [11C]PBB3 [89], with different affinity for neurofibrillary tangles and for Tau isoforms (3R and 4R) [86].”
BackgroundIsolated bipallidal lesions caused by extrapontine myelinolysis.
(2008) · Institutional Research Information System (Università degli Studi di Brescia) · doi:10.1212/01 · Cited by 573
Self-citationRohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationBlood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 1×
“In the last years, specific tracers for Tau pathology have been developed [86, 87].”
BackgroundThut, G., & Pascual-Leone, A. (2010) · Brain Topography · doi:10.1007/s10548-009-0115-4 · Cited by 388 · cited 4×
“Furthermore, specific paradigms of paired associative stimulation [108] or repetitive TMS [109, 110] have shown to increase or decrease the excitability of corticospinal projections of the primary motor cortex (M1), representing a form of long-term potentiation or depression and thus a method of assessing synaptic pla…”
InfluentialEpidemiology of early-onset dementia: a review of the literature
Vieira, R. T., Caixeta, L., Machado, S., Silva, A. C., Nardi, A. E., Arias-Carrión, O., & Carta, M. G. (2013) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901309010088 · Cited by 325 · cited 1×
“FTD is the second most common cause of dementia in the presenile age group (<65 years of age), and accounts for 5–15% of all cases of dementia, with a prevalence of 3–26 per 100,000 subjects in the age group of 45–65 years [5, 6].”
BackgroundMRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases
Harper, L., Fumagalli, G. G., Barkhof, F., Scheltens, P., O’Brien, J. T., Bouwman, F., Burton, E. J., Rohrer, J. D., Fox, N. C., Ridgway, G. R., et al. (2016) · Brain · doi:10.1093/brain/aww005 · Cited by 264
Neurofilament light chain: a biomarker for genetic frontotemporal dementia
Meeter, L. H., Dopper, E. G., Jiskoot, L. C., Sanchez‐Valle, R., Graff, C., Benussi, L., Ghidoni, R., Pijnenburg, Y. A., Borroni, B., Galimberti, D., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.325 · Cited by 263
Self-citationScherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249 · cited 1×
“Furthermore, NfL levels have been shown to be increased in patients with multiple system atrophy, PSP, corticobasal syndrome, and vascular dementia [47, 50, 51].”
BackgroundKipps, C. M., Davies, R. R., Mitchell, J., Kril, J. J., Halliday, G. M., & Hodges, J. R. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100973 · Cited by 172
Brain network connectivity assessed using graph theory in frontotemporal dementia
Agosta, F., Sala, S., Valsasina, P., Meani, A., Canu, E., Magnani, G., Cappa, S. F., Scola, E., Quatto, P., Horsfield, M. A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31829a33f8 · Cited by 168 · cited 1×
“Altogether, FTD functional connectivity approaches have shown a progressive functional network disruption [72–74], both at the regional level [69] as well as the whole-brain level [75, 76] using graph-theory measures.”
Background18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain · doi:10.1093/brain/aww163 · Cited by 168
Frontotemporal Dementia Associated With the C9ORF72 Mutation: A Unique Clinical Profile
Devenney, E., Hornberger, M., Irish, M., Mioshi, E., Burrell, J., Tan, R., Kiernan, M. C., & Hodges, J. R. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6002 · Cited by 167
Frontotemporal dementia and related disorders: Deciphering the enigma
Josephs, K. A. (2008) · Annals of Neurology · doi:10.1002/ana.21426 · Cited by 166 · cited 1×
“If neuropathology is clearly predictable in monogenic FTD, in the other cases there is no correspondence between clinical features and neuropathological findings [25, 26].”
BackgroundStructural and functional brain connectivity in presymptomatic familial frontotemporal dementia
Dopper, E. G. P., Rombouts, S. A. R. B., Jiskoot, L. C., den Heijer, T., de Graaf, J. R. A., de Koning, I., Hammerschlag, A. R., Seelaar, H., Seeley, W. W., Veer, I. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000583 · Cited by 152
Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308004 · Cited by 132 · cited 1×
“CSF Tau isoforms ratio in PSP was 50% lower than in patients with either neurodegenerative parkinsonism [42, 43] or other Tau-related dementias such as Alzheimer’s disease [44].”
ResultHall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127 · cited 2×
“As other CSF biomarkers reported above, also NfL levels could possibly discriminate between FTLDTDP and FTLD-Tau, resulting increased in patients with TDP-43 pathology [37, 49].”
BackgroundResultReduced CSF p-Tau 181 to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113
Wray, S., Saxton, M., Anderton, B. H., & Hanger, D. P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05321.x · Cited by 97
Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations
Spina, S., Schonhaut, D. R., Boeve, B. F., Seeley, W. W., Ossenkoppele, R., O'Neil, J. P., Lazaris, A., Rosen, H. J., Boxer, A. L., Perry, D. C., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003636 · Cited by 96
Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis
Grossman, M., Elman, L., McCluskey, L., McMillan, C. T., Boller, A., Powers, J., Rascovsky, K., Hu, W., Shaw, L., Irwin, D. J., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6064 · Cited by 94 · cited 2×
“In this view, pTau/tTau ratio has been proposed as useful in detecting patients with amyotrophic lateral sclerosis, which is associated with TDP neuropathology [20].”
ResultPijnenburg, Y. A. L., Verwey, N. A., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.001 · Cited by 91 · cited 4×
“As other CSF biomarkers reported above, also NfL levels could possibly discriminate between FTLDTDP and FTLD-Tau, resulting increased in patients with TDP-43 pathology [37, 49].”
BackgroundInfluentialCsf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia
Borroni, B., Benussi, A., Archetti, S., Galimberti, D., Parnetti, L., Nacmias, B., Sorbi, S., Scarpini, E., & Padovani, A. (2015) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.971812 · Cited by 77 · cited 5×
“Later, this result was further corroborated in patients with known Tau or TDP-43 pathology, with high accuracy values in identifying TDP-43 cases [20, 21] (Fig.”
BackgroundResultInfluentialSelf-citationQuantitative EEG in Frontotemporal Dementia
Yener, G. G., Leuchter, A. F., Jenden, D., Read, S. L., Cummings, J. L., & Miller, B. L. (1996) · Clinical Electroencephalography · doi:10.1177/155005949602700204 · Cited by 71
Measuring disease progression in frontotemporal lobar degeneration: A clinical and MRI study
Gordon, E., Rohrer, J. D., Kim, L. G., Omar, R., Rossor, M. N., Fox, N. C., & Warren, J. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d1a879 · Cited by 70
Hafkemeijer, A., Möller, C., Dopper, E. G. P., Jiskoot, L. C., van den Berg-Huysmans, A. A., van Swieten, J. C., van der Flier, W. M., Vrenken, H., Pijnenburg, Y. A. L., Barkhof, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150695 · Cited by 57
Sedeño, L., Piguet, O., Abrevaya, S., Desmaras, H., García‐Cordero, I., Baez, S., Alethia de la Fuente, L., Reyes, P., Tu, S., Moguilner, S., et al. (2017) · Human Brain Mapping · doi:10.1002/hbm.23627 · Cited by 55 · cited 2×
“Altogether, FTD functional connectivity approaches have shown a progressive functional network disruption [72–74], both at the regional level [69] as well as the whole-brain level [75, 76] using graph-theory measures.”
BackgroundLooking for measures of disease severity in the frontotemporal dementia continuum
Premi, E., Gualeni, V., Costa, P., Cosseddu, M., Gasparotti, R., Padovani, A., & Borroni, B. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160178 · Cited by 26
Self-citation
Cited by
Neuroinflammation in frontotemporal dementia
Bright, F., Werry, E. L., Dobson-Stone, C., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kassiou, M., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0231-z · Cited by 280
Bowles, K. R., Silva, M. C., Whitney, K., Bertucci, T., Berlind, J. E., Lai, J. D., Garza, J. C., Boles, N. C., Mahali, S., Strang, K. H., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.003 · Cited by 182
Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200608 · Cited by 113
“A multitude of markers of disease severity have been recognized in the last decade, ranging from neuroimaging with magnetic resonance imaging (MRI) or positron emission tomography (PET), to cerebrospinal fluid (CSF) biomarkers (for a review, see [6, 7]).”
Self-citationToward a glutamate hypothesis of frontotemporal dementia
Benussi, A., Alberici, A., Buratti, E., Ghidoni, R., Gardoni, F., Di Luca, M., Padovani, A., & Borroni, B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00304 · Cited by 90
“In vivo neurophysiological evidence of the involvement of glutamatergic circuits in FTD mainly comes from noninvasive brain stimulation studies using transcranial magnetic stimulation (TMS) (Borroni et al., 2018).”
BackgroundInfluentialSelf-citationBoxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Metadata
- Authors
- Borroni, B., Benussi, A., Premi, E., Alberici, A., Marcello, E., Gardoni, F., Di Luca, M., & Padovani, A.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-20
- Volume
- 62
- Issue
- 3
- Pages
- 1113-1123
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2770547283
- Cited by
- 36
- References
- 37
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.